[
  {
    "ts": null,
    "headline": "How To Build A $100,000 Dividend Portfolio: SCHD As The Core For Income And Growth",
    "summary": "SCHD ETF effectively combines dividend income and dividend growth, while offering investors a reduced Expense Ratio. Click here to read why SCHD is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=8f7d563d7078791e271bf624695990f6087b61fabd27b38e050a889bfbd76ca2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737568800,
      "headline": "How To Build A $100,000 Dividend Portfolio: SCHD As The Core For Income And Growth",
      "id": 132444744,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1131637568/image_1131637568.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "SCHD ETF effectively combines dividend income and dividend growth, while offering investors a reduced Expense Ratio. Click here to read why SCHD is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=8f7d563d7078791e271bf624695990f6087b61fabd27b38e050a889bfbd76ca2"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=9290450381fc7219f940475f4803102faf9e954d3609b4e7226d5f1cd7274b65",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737565200,
      "headline": "Health Care Roundup: Market Talk",
      "id": 132459215,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=9290450381fc7219f940475f4803102faf9e954d3609b4e7226d5f1cd7274b65"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More",
    "summary": "These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More",
    "url": "https://finnhub.io/api/news?id=a820240c178d72b1021c5cdc08914e94e7bcd6110f8eccabd4575c78ba78641a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737563940,
      "headline": "These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More",
      "id": 132459086,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More",
      "url": "https://finnhub.io/api/news?id=a820240c178d72b1021c5cdc08914e94e7bcd6110f8eccabd4575c78ba78641a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints",
    "summary": "J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints",
    "url": "https://finnhub.io/api/news?id=fae248a89b1082b0c404678c6e22a58494a64eb85fea89a8eb0d6153c15d5ac1",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737563609,
      "headline": "J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints",
      "id": 132459216,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints",
      "url": "https://finnhub.io/api/news?id=fae248a89b1082b0c404678c6e22a58494a64eb85fea89a8eb0d6153c15d5ac1"
    }
  },
  {
    "ts": null,
    "headline": "MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value",
    "summary": "MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for my MGTX stock update.",
    "url": "https://finnhub.io/api/news?id=9975936e718b24a2e7a3c30feb95810ce1eb7d0f25413a2a536ceafe08b7b701",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737562146,
      "headline": "MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value",
      "id": 132444290,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183067289/image_2183067289.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for my MGTX stock update.",
      "url": "https://finnhub.io/api/news?id=9975936e718b24a2e7a3c30feb95810ce1eb7d0f25413a2a536ceafe08b7b701"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: AI Project Stargate A Go",
    "summary": "Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.",
    "url": "https://finnhub.io/api/news?id=e936bbf691c7f0765abef55e489748dcecfa425e001286273ea6dd274fe4b7a5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737561600,
      "headline": "Wall Street Lunch: AI Project Stargate A Go",
      "id": 132444292,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1817371218/image_1817371218.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.",
      "url": "https://finnhub.io/api/news?id=e936bbf691c7f0765abef55e489748dcecfa425e001286273ea6dd274fe4b7a5"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves innovative monotherapy for treatment-resistant depression",
    "summary": "The US Food and Drug Administration has approved the first monotherapy for adults with treatment-resistant depression. Johnson & Johnson's SPRAVATO ® CIII nasal spray is indicated for major...",
    "url": "https://finnhub.io/api/news?id=c47386909d4d7f845d189f9708a5e52e672f973e70c3beefc71ffbcd1bc8e3cb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737556267,
      "headline": "FDA approves innovative monotherapy for treatment-resistant depression",
      "id": 132443727,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "The US Food and Drug Administration has approved the first monotherapy for adults with treatment-resistant depression. Johnson & Johnson's SPRAVATO ® CIII nasal spray is indicated for major...",
      "url": "https://finnhub.io/api/news?id=c47386909d4d7f845d189f9708a5e52e672f973e70c3beefc71ffbcd1bc8e3cb"
    }
  },
  {
    "ts": null,
    "headline": "Stocks of companies reporting earnings are providing a net 50-point boost to the Dow",
    "summary": "Stocks of companies reporting earnings are providing a net 50-point boost to the Dow",
    "url": "https://finnhub.io/api/news?id=bb4850e0145aaa4cefdaf947f28e58a05b2505de839a715eab31d2a64675a490",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737550268,
      "headline": "Stocks of companies reporting earnings are providing a net 50-point boost to the Dow",
      "id": 132459198,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Stocks of companies reporting earnings are providing a net 50-point boost to the Dow",
      "url": "https://finnhub.io/api/news?id=bb4850e0145aaa4cefdaf947f28e58a05b2505de839a715eab31d2a64675a490"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing",
    "summary": "Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=da0096187b511ace2c14da1e45620c590e972855001f73920b1355c9701138a6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737548676,
      "headline": "Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing",
      "id": 132443266,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=da0096187b511ace2c14da1e45620c590e972855001f73920b1355c9701138a6"
    }
  },
  {
    "ts": null,
    "headline": "Bert's December 2024 Dividend Income Summary",
    "summary": "December always has the highest allocation of fund payments due to the capital gains distributions. Click to read.",
    "url": "https://finnhub.io/api/news?id=b63301b9ded097694826191e6ba3e0d5e698f6c97b36e71fee383609798db8d9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737548100,
      "headline": "Bert's December 2024 Dividend Income Summary",
      "id": 132443206,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1824323153/image_1824323153.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "December always has the highest allocation of fund payments due to the capital gains distributions. Click to read.",
      "url": "https://finnhub.io/api/news?id=b63301b9ded097694826191e6ba3e0d5e698f6c97b36e71fee383609798db8d9"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript",
    "summary": "Johnson &amp; Johnson (NYSE:JNJ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, Investor...",
    "url": "https://finnhub.io/api/news?id=dd0a83799d8b6c919a5dba10eea35f02913050511a8d39acde0a3675451b26ee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737547771,
      "headline": "Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript",
      "id": 132443182,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, Investor...",
      "url": "https://finnhub.io/api/news?id=dd0a83799d8b6c919a5dba10eea35f02913050511a8d39acde0a3675451b26ee"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance",
    "summary": "Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance",
    "url": "https://finnhub.io/api/news?id=f328aed9a948253ab8abdf6675e92b22055f0fc29c1613df983121464764d23f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737546300,
      "headline": "Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance",
      "id": 132459240,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance",
      "url": "https://finnhub.io/api/news?id=f328aed9a948253ab8abdf6675e92b22055f0fc29c1613df983121464764d23f"
    }
  },
  {
    "ts": null,
    "headline": "Why the Dow is lagging the S&P 500 and the Nasdaq",
    "summary": "Why the Dow is lagging the S&P 500 and the Nasdaq",
    "url": "https://finnhub.io/api/news?id=c543ddb2074fd21b47ac6c4090347200f6fef6e0467d255f667eb7125f9f3e4d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737546191,
      "headline": "Why the Dow is lagging the S&P 500 and the Nasdaq",
      "id": 132459089,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Why the Dow is lagging the S&P 500 and the Nasdaq",
      "url": "https://finnhub.io/api/news?id=c543ddb2074fd21b47ac6c4090347200f6fef6e0467d255f667eb7125f9f3e4d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - SPRAVATO approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression",
    "summary": "Titusville, New Jersey - Johnson & Johnson announced today the U.S. Food and Drug Administration approval of a supplemental New Drug Application for SPRAVATO CIII nasal spray, making this...",
    "url": "https://finnhub.io/api/news?id=817ed78f1207398ba54aa5a6e3f1197515f82015913bec6a9de6507847837494",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737541892,
      "headline": "Johnson & Johnson - SPRAVATO approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression",
      "id": 132442651,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Titusville, New Jersey - Johnson & Johnson announced today the U.S. Food and Drug Administration approval of a supplemental New Drug Application for SPRAVATO CIII nasal spray, making this...",
      "url": "https://finnhub.io/api/news?id=817ed78f1207398ba54aa5a6e3f1197515f82015913bec6a9de6507847837494"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - European Commission approves LAZCLUZE in combination with RYBREVANT for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer",
    "summary": "BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission has approved a Marketing Authorisation for LAZCLUZE , in combination with...",
    "url": "https://finnhub.io/api/news?id=dd433e403bd9ab6b4f9406089aad9c019043f011593d800315e81b0bd8f8c6f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737541891,
      "headline": "Johnson & Johnson - European Commission approves LAZCLUZE in combination with RYBREVANT for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer",
      "id": 132442653,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "BEERSE, BELGIUM - Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission has approved a Marketing Authorisation for LAZCLUZE , in combination with...",
      "url": "https://finnhub.io/api/news?id=dd433e403bd9ab6b4f9406089aad9c019043f011593d800315e81b0bd8f8c6f1"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson 2024 Q4 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Johnson &amp; Johnson in conjunction with their 2024 Q4 earnings call.",
    "url": "https://finnhub.io/api/news?id=3fe6a9b75de97f6b58cf2f68852a50aaf7f0187c787555ff3dc0ecc52f8440b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737539235,
      "headline": "Johnson & Johnson 2024 Q4 - Results - Earnings Call Presentation",
      "id": 132442473,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Johnson &amp; Johnson in conjunction with their 2024 Q4 earnings call.",
      "url": "https://finnhub.io/api/news?id=3fe6a9b75de97f6b58cf2f68852a50aaf7f0187c787555ff3dc0ecc52f8440b7"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth",
    "summary": "Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth",
    "url": "https://finnhub.io/api/news?id=09b67435b44177f7930398b170f762d698119abe27f847582f65f67bdd614584",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737536940,
      "headline": "Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth",
      "id": 132459242,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth",
      "url": "https://finnhub.io/api/news?id=09b67435b44177f7930398b170f762d698119abe27f847582f65f67bdd614584"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : Fourth Quarter 2024 4Q24 Other Financial Disclosures",
    "summary": "Fourth Quarter 2024 Other Financial Disclosures Table of Contents Table 1: Sales by Segment ...",
    "url": "https://finnhub.io/api/news?id=6aa8a4b714998424ce7f9b1f8f57bec206be8ff0047282e9e298b85efd3337f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737532085,
      "headline": "Johnson & Johnson : Fourth Quarter 2024 4Q24 Other Financial Disclosures",
      "id": 132441986,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Fourth Quarter 2024 Other Financial Disclosures Table of Contents Table 1: Sales by Segment ...",
      "url": "https://finnhub.io/api/news?id=6aa8a4b714998424ce7f9b1f8f57bec206be8ff0047282e9e298b85efd3337f2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: EPS down 11% in Q4",
    "summary": "Johnson & Johnson reports adjusted EPS for the last three months of 2024 down 10.9% at $2.04, a level roughly in line with expectations, although burdened to the tune of 22 cents by IPR&D charges...",
    "url": "https://finnhub.io/api/news?id=ee654ffe03d5699867acdb7689f0ca55ccc924002ef0ed7ed71b9ab962c05839",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737531854,
      "headline": "Johnson & Johnson: EPS down 11% in Q4",
      "id": 132441982,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson reports adjusted EPS for the last three months of 2024 down 10.9% at $2.04, a level roughly in line with expectations, although burdened to the tune of 22 cents by IPR&D charges...",
      "url": "https://finnhub.io/api/news?id=ee654ffe03d5699867acdb7689f0ca55ccc924002ef0ed7ed71b9ab962c05839"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : Fourth Quarter 2024 Earnings Presentation",
    "summary": "4th Quarter 2024 Earnings Call January 22, 2025 Cautionary note on Forward-looking statements This...",
    "url": "https://finnhub.io/api/news?id=d39af568fe89698f01c4dd62499c65365144ea940998e88c4f8f5474994bb8ca",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737527527,
      "headline": "Johnson & Johnson : Fourth Quarter 2024 Earnings Presentation",
      "id": 132441578,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "4th Quarter 2024 Earnings Call January 22, 2025 Cautionary note on Forward-looking statements This...",
      "url": "https://finnhub.io/api/news?id=d39af568fe89698f01c4dd62499c65365144ea940998e88c4f8f5474994bb8ca"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Reports Q4 and Full-Year 2024 Results",
    "summary": "2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%*2024 Fourth-Quarter Earnings per share of $1.41 and...",
    "url": "https://finnhub.io/api/news?id=0e0cbd8692be666b2dfece8b3b4b110f52cf79ae2abf6b16b412932b554cbfd3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737526863,
      "headline": "Johnson & Johnson Reports Q4 and Full-Year 2024 Results",
      "id": 132441523,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%*2024 Fourth-Quarter Earnings per share of $1.41 and...",
      "url": "https://finnhub.io/api/news?id=0e0cbd8692be666b2dfece8b3b4b110f52cf79ae2abf6b16b412932b554cbfd3"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Spravato, first monotherapy nasal spray to treat depression",
    "summary": "The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.Johnson & Johnson's Spravato has been approved to treat a major depressive...",
    "url": "https://finnhub.io/api/news?id=14b10077afa99fced4d6e3755b6e8d4724b6d45d48eff8220f6de3b1e33d680d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737505084,
      "headline": "FDA approves Spravato, first monotherapy nasal spray to treat depression",
      "id": 132439875,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.Johnson & Johnson's Spravato has been approved to treat a major depressive...",
      "url": "https://finnhub.io/api/news?id=14b10077afa99fced4d6e3755b6e8d4724b6d45d48eff8220f6de3b1e33d680d"
    }
  }
]